Edison Investment Research - Basilea Pharmaceutica AG (BSLN) Basilea Pharmaceutica - Partner in place for US commercialisation of Zevtera

Report

Edison Investment Research

Sean Conroy

Basilea Pharmaceutica - Partner in place for US commercialisation of Zevtera

Following FDA approval in April 2024, Basilea has announced a much-anticipated partnership agreement with Innoviva Specialty Therapeutics for the commercialisation of Zevtera in the US. Deal terms include an upfront payment of US$4m, as well as tiered royalties on net sales in the high-teens to mid-20s percentage range. In addition, the company is eligible to receive up to US$223m in sales-related milestone payments. We view this as an important milestone and highly favourable transaction for Basilea, while offering an effective new medicine to combat Staphylococcus aureus bloodstream infections in the US. For now, we put our valuation on hold as we review our model and estimates.

17/12/2024 1 EN

Underlying

Basilea Pharmaceutica AG

Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.

See profile

CH0011432447 Six Swiss Exchange Switzerland

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

GlobeNewsWire

Starker Verkaufsstart von Cresemba in Japan löst erste Umsatzmeilensteinzahlung von AKP an Basilea aus

Starker Verkaufsstart von Cresemba in Japan löst erste Umsatzmeilensteinzahlung von AKP an Basilea aus Allschwil, 05. Februar 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, berichtete heute, dass die Verkäufe des Antimykotikums Cresemba® (Isavuconazol) in Japan die Schwelle überschritten haben, durch welche die erste Umsatzmeilensteinzahlung von seinem Partner Asahi Kasei Pharma (AKP) in Höhe von rund CHF 1.2 ...

February 5, 2025 February 5, 2025 1 EN

GlobeNewsWire

Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea

Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea Allschwil, Switzerland, February 05, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba® (isavuconazole) in Japan exceeded the threshold triggering the first sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.2 million. David Veitch, Chief ...

February 5, 2025 February 5, 2025 1 EN

GlobeNewsWire

Starkes Verkaufswachstum von Cresemba und Zevtera löst weitere Meilensteinzahlungen an Basilea aus

Starkes Verkaufswachstum von Cresemba und Zevtera löst weitere Meilensteinzahlungen an Basilea aus Allschwil, 28. Januar 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, berichtete heute, dass die Verkäufe des Antimykotikums Cresemba® (Isavuconazol) und des Antibiotikums Zevtera® (Ceftobiprol) im Jahr 2024 Schwellen überschritten haben, durch die Umsatzmeilensteinzahlungen von Distributionspartnern in einer Höhe...

January 28, 2025 January 28, 2025 1 EN

Topps Tiles - Accelerating growth through Q125

Topps Tiles (TPT) is enjoying a return to revenue growth following a very challenging FY24 due to wider macroeconomic weakness. The company’s recovery is clearly being boosted by new revenue streams from its self-help initiatives, notably from trade and online customers across all of its brands. While the macroeconomic environment remains uncertain, it is pleasing that the strategy is supporting growth. The valuation continues to look compelling, even with limited macroeconomic recovery included in management’s long-term financial goals. With the Q125 trading update, the CEO has announced his ...

January 10, 2025 January 10, 2025 1 EN

Pedro Fonseca

Pedro Fonseca

Baillie Gifford US Growth Trust - A unique high-growth strategy meriting support

Baillie Gifford US Growth Trust (USA) invests in exceptional US businesses with the potential to grow substantially faster than the market and deliver above-market returns. Such businesses tend to operate at the cutting edge of technology-led change and USA has exposure to companies focused on AI, space travel and online services. This note reiterates USA’s unique investment proposition and scrutinises a recent proposal from Saba, a US hedge fund manager, aimed at ousting USA’s board and replacing its investment managers. Saba currently owns less than 28% of USA shares in issue. The trust’s bo...

January 10, 2025 January 10, 2025 1 EN

Kate Heseltine

Kate Heseltine

Greggs - More challenging environment in H224

Greggs has reported that FY24 profit is in line with management’s expectation despite the more challenging environment and slowing sales growth through H224. The more challenging market means that management is more cautious about the outlook for H125 than previously. With space expansion and recovery of cost inflation, it expects to deliver profit growth in FY25 albeit lower than previously anticipated. We have reduced our FY25 profit before tax estimate by c 2%.

January 9, 2025 January 9, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Basilea Pharmaceutica - Partner in place for US commercialisation of Zevtera

Starker Verkaufsstart von Cresemba in Japan löst erste Umsatzmeilensteinzahlung von AKP an Basilea aus

Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea

Starkes Verkaufswachstum von Cresemba und Zevtera löst weitere Meilensteinzahlungen an Basilea aus

Topps Tiles - Accelerating growth through Q125

Baillie Gifford US Growth Trust - A unique high-growth strategy meriting support

Greggs - More challenging environment in H224

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe